Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;368:1314-25. DOI: 10.1056/NEJMoa1212299

Supplementary Appendix

Supplement to: Hussain M, Tangen CM, Berry DL, et al. Intermittent versus Continuous Androgen Deprivation in Prostate Cancer

Table of Contents

Figure S1. S9346 Consort Diagram



* Lost to follow-up is defined as followed for less than 10 years, and last contact date was more than three years prior to date of final data analysis.

**These patients are eligible and included in the intent-to-treat analysis

Figure S2: QOL CONSORT Diagram

Induction Enrollment, Randomization and Follow up for S9346 QOL Sample

Step 1: Induction Enrollment
Of 2950 eligible men at registration:

- Participant in QOL at registration (n=1340)
- Non-participant in QOL- EORTC Patients (n=596)
- Non-participant in QOL due to late induction registrations (n=936).
- Did not submit usable QOL form-set (n=78)

- **Step 2: Consolidation Randomization***
- Of the 1535 eligible men randomized to step 2,
- QOL was expected on 1247 (615 CAD, 632 IAD):
- 1215 (97.4%; 595 CAD, 620 IAD) any usable form-set after registration
- 32 (2.6%; 20 CAD, 12 IAD) no usable form-sets after registration
- 1162 (93.2% 568 CAD, 594 IAD) usable form-set at randomization
- 995 (79.8%; 494 CAD, 501 IAD) usable form-set at 3 months
- 915 (73.4%; 438 CAD, 477 IAD) usable form-set at 9 months
- 826 (66.2%; 406 CAD, 420 IAD) usable form-set at 15 months

*The quality of life results in this report are based on data from the randomized trial, not the induction enrollment phase.

Table S1: Adverse Event Categories Where at Least One Grade 4 Event was Reported* During the Consolidation (Randomized) Portion of the Trial

	IAD (N=703)		**CAD (N=731)**	
AE Category	**Grade 3**	**Grade 4**	**Grade 3**	**Grade 4**
Cardiovascular	8	3	10	5
Flu-like Symptoms	18	2	26	2
Gastrointestinal	4	0	6	3
Hemorrhage	0	1	3	0
Liver	7	0	3	1
Lung	9	2	12	1
Musculoskeletal	1	1	2	1
Neurologic	15	1	15	2
Pain	26	1	30	2
Renal/Bladder	11	0	4	1
Max Grade Any AE^	**203**	**11**	**224**	**15**

* Treatment attribution: possible, probable, or definite, No Grade 5 reported
^ For all patients, including all AE categories.

Table S2: Median Survival (95% Confidence Interval) in Years for Treatment Arm Within Each Subset

Subset	Median CAD	Median IAD
Extensive Disease	4.4 (3.9, 5.2)	4.9 (4.5, 5.5)
Minimal Disease	6.9 (6.3, 7.5)	5.4 (4.8, 6.8)
Bone Pain	4.7 (3.6, 6.5)	4.2 (3.6, 4.7)
No Bone Pain	6.0 (5.5, 6.8)	5.7 (5.1, 6.7)
PSA < 0.2 ng/ml	7.1 (6.3, 7.9)	6.5 (5.5, 7.1)
PSA 0.2 - 4.0 ng/ml	3.5 (3.1, 4.0)	3.5 (3.1, 4.1)
Black	6.7 (4.6, 8.2)	6.0 (4.4, 8.6)
not Black	5.9 (5.2, 6.8)	5.2 (4.8, 6.1)
PS 0-1	5.8 (5.3, 6.5)	5.1 (4.8, 5.6)
PS 2-3	5.0 (2.2, 8.2)	4.0 (2.9, 6.9)
Prior hormones or finasteride	6.6 (3.8, 7.7)	4.8 (3.7, 6.7)
No Prior hormones	5.7 (5.2, 6.4)	5.1 (4.8, 5.7)
Europe	5.3 (4.0, 6.2)	3.8 (3.1, 4.6)
North America	6.1 (5.3, 6.8)	5.3 (4.9, 6.1)
Overall	5.8 (5.3, 6.5)	5.1 (4.8, 5.5)